Form 4: Ionis CFO Reports Equity Transactions

Ionis Pharmaceuticals' CFO, Elizabeth L. Hougen, reported the vesting of restricted stock units, a tax-related sale of common stock, and new grants of performance and restricted stock units.

Summary

• Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals Inc. (IONS), reported several equity transactions.
• On January 15, 2026, 28,729 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
• Following this, on January 16, 2026, 12,922 shares of common stock were sold at a weighted average price of $75.22 per share to cover required tax withholding obligations.
• On January 15, 2026, Ms. Hougen was granted 34,360 Performance Restricted Stock Units (PRSUs) under the company's 2011 Equity Incentive Plan. These PRSUs may vest over a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group, with the reported number representing the maximum (200% of target).
• Also on January 15, 2026, Ms. Hougen received a grant of 12,885 Restricted Stock Units (RSUs) which will vest in four equal annual installments.
• After these transactions, Ms. Hougen directly beneficially owns 126,307 shares of common stock, 120,995 Performance Restricted Stock Units, and 68,825 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the ongoing equity grants to a key executive, aligning interests, balanced by the routine nature of the tax-related sale. These are expected compensation events.

Positives

• The grant of 34,360 Performance Restricted Stock Units (PRSUs) and 12,885 Restricted Stock Units (RSUs) indicates ongoing equity-based compensation for a key executive, aligning management's interests with shareholder value.
• The vesting of 28,729 Restricted Stock Units demonstrates the realization of previously granted equity compensation.

Negatives

• The sale of 12,922 shares, while for tax withholding, reduces the executive's direct common stock ownership.

Future Outlook

The Performance Restricted Stock Units (PRSUs) are subject to a three-year performance period, with vesting contingent on the company's relative total shareholder return compared to a peer group. The actual number of PRSUs vesting can range from zero to the maximum of 34,360. The newly granted Restricted Stock Units (RSUs) will vest in four equal annual installments, providing future equity compensation.

Industry Context

This Form 4 filing represents routine insider transactions common in publicly traded companies, reflecting the standard practice of executive equity compensation and subsequent tax-related sales. Such filings are a regular part of corporate governance and transparency in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Routine equity compensation and tax-related sales by an executive are generally neutral, reflecting standard corporate governance practices and the alignment of executive incentives with company performance.
• Employees: The equity incentive plan provides a framework for executive compensation, which can influence overall employee compensation strategies and retention efforts.

Next Steps

• Future vesting of Performance Restricted Stock Units (PRSUs) based on the company's relative total shareholder return over a three-year period.
• Future vesting of Restricted Stock Units (RSUs) in four equal annual installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including stock unit vesting, new grants, and a tax-related sale. It does not contain new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing provides no new catalysts for a buy or sell decision.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Performance Restricted Stock Units, CFO